Rare Disease Research, LLC | Atlanta, GA
Status and phase
Conditions
Treatments
About
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
Full description
This is a Phase 3 long term extension (LTE) study to evaluate the safety and efficacy of GTX-102 in participants with AS.
Participants may remain in the study until GTX-102 is approved and/or becomes available in their geographical region or the sponsor stops the study.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
75 participants in 1 patient group
Loading...
Central trial contact
Patients Contact: Trial Recruitment; HCPs Contact: Medical Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal